buyWeak
Matthew Gall bought $39k of ITOS
Chief Financial Officer at iTeos Therapeutics, Inc.. 5,000 shares at an average of $7.73, traded Nov 19, 2024, filed Nov 19, 2024.
Conviction score
31Value
$39k
5,000 shares
Holdings after
65,429
+8% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +6Trade size$39k at market
- +3Relative to holdingsHoldings up 8%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-128956, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 19, 2024 | POpen-market purchase Common Stock | +5,000 | $7.73 | $39k | 65,429 | Nov 19, 2024 |
Related signals
Other insiders at iTeos Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.0M 104,565 shares | -72% | |
| 43Moderate | iTeos Therapeutics, Inc. | Michel Detheux Chief Executive Officer | $1.6M 156,847 shares | -109% | |
| 33Weak | iTeos Therapeutics, Inc. | David Hallal director | $1.2M 114,682 shares | -300% | |
| 42Moderate | ITOSbuy iTeos Therapeutics, Inc. | EcoR1 Capital, LLC owner | $39M 4,958,978 shares | +87% | |
| 53Moderate | iTeos Therapeutics, Inc. | MPM BioVentures 2014, L.P. other | $5.1M 630,191 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Ansbert Gadicke other | $8.3M 1,031,931 shares | -23% | |
| 53Moderate | iTeos Therapeutics, Inc. | Mpm Bioventures 2018, L.p. other | $5.1M 630,191 shares | -23% | |
| 34Weak | ITOSbuy iTeos Therapeutics, Inc. | Matthew Gall Chief Financial Officer | $42k 5,000 shares | +35% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.